Personalized testing to find the best CF medicine for you
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This early study tests an individualized approach (“theratyping”) to match your cystic fibrosis (CF) to the CFTR medicine that may work best for your specific genetic change. It may help find a more tailored treatment plan and see how your body responds, while using medicines that are already approved for some people with CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cystic fibrosis (CF).
- You are at least 6 years old.
- Your CF genetic test shows a CFTR mutation that might respond to approved CFTR medicines (correctors/potentiators).
- You can give consent/assent, and your CF breathing treatments are stable (no recent major changes).
- You have not had a CF lung flare-up needing antibiotics or steroid treatment for more than 28 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
This study enrolls newly diagnosed infants with cystic fibrosis to follow them during “precision medicine” care. It may help doctors better understand which treatments and monitoring work best, especially before certain infections develop.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.